Status: Recruiting
A Study of Buntanetap in Participants With PD
This study will examine the long-term safety of buntanetap in participants with PD. This will be a 36-month open-label safety study. This study will be conducted with two cohorts. Cohort 1 will enroll via invitation only for PD participants who have previously participated in buntanetap clinical trials. Cohort 2 will be for PD participants who are receiving deep brain stimulation (DBS) treatment. Qualified participants will receive buntanetap 30mg QD after a screening period of up to 42 days.
Participants needed: 500
Trial details
Phase: Phase 2, Phase 3Age: 40-85Biological sex: AllType: InterventionalSponsor: Annovis Bio Inc.Updated: Jun 15, 2026Locations: 27
Eligibility criteria
Diagnosis of idiopathic PD according to MDS Clinical Diagnostic Criteria for Par... [+22]
Cohort 1 only: Is currently receiving DBS treatment. (Participant may enroll in... [+22]